Celldex Therapeutics Inc
F:TCE2
Celldex Therapeutics Inc
F:TCE2
Price:
32.44
EUR
6.05%
Market Cap:
€2.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Celldex Therapeutics Inc
F:TCE2
|
US |
|
A
|
Aurubis AG
XMUN:NDA
|
DE |
|
Saudi Arabian Oil Co
SAU:2222
|
SA |
|
C
|
COSCO SHIPPING Development Co Ltd
XHAM:EZ5
|
CN |
|
Konami Group Corp
F:KOA0
|
JP |
|
W
|
Weichai Power Co Ltd
OTC:WEICF
|
CN |
|
F
|
Franklin Resources Inc
SWB:FRK
|
US |
|
Marcus Corp
NYSE:MCS
|
US |
|
W
|
Williams-Sonoma Inc
F:WM1
|
US |
|
P
|
PICC Property and Casualty Co Ltd
XBER:PJC
|
CN |
|
TBS Holdings Inc
TSE:9401
|
JP |
|
Foschini Group Ltd
OTC:FHHGF
|
ZA |
|
A
|
Allianz SE
BMV:ALVN
|
DE |
Wall St Price Targets
TCE2 Price Targets Summary
Celldex Therapeutics Inc
Celldex Therapeutics Inc
Wall Street analysts forecast TCE2 stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for TCE2 is 35.11 EUR with a low forecast of 22.96 EUR and a high forecast of 56.54 EUR.
Lowest Forecast
Price Target
22.96
EUR
29% Downside
Average Forecast
Price Target
35.11
EUR
8% Upside
Highest Forecast
Price Target
56.54
EUR
74% Upside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is TCE2's stock price target?
Price Target
35.11
EUR
35.11
EUR
According to Wall Street analysts, the average 1-year price target for TCE2 is 35.11 EUR with a low forecast of 22.96 EUR and a high forecast of 56.54 EUR.
What is the Revenue forecast for Celldex Therapeutics Inc?
Projected CAGR
375%
375%
Over the last 13 years, the compound annual growth rate for Revenue has been -14%. The projected CAGR for the next 3 years is 375%.
